Rilimogene glafolivec clinical trials
Also written PROSTVAC-F.
How each study uses rilimogene glafolivec is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
9 studies that test it; most in 2003 (1)
| Year | Studies |
|---|---|
| 2003 | 1 |
| 2006 | 1 |
| 2007 | 1 |
| 2010 | 1 |
| 2011 | 1 |
| 2014 | 1 |
| 2015 | 1 |
| 2016 | 1 |
| 2018 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 1 · Other 8
National Cancer Institute (NCI) (7) · Washington University School of Medicine (1) · Bavarian Nordic (1)
Often tested with
Tested in the same studies.
Rilimogene galvacirepvec (6) · Tricom (3) · Docetaxel (1) · Vaccines, DNA (1) · Granulocyte-Macrophage Colony-Stimulating Factor (1) · rV-Tricom (1)
Studies
Open first, then newest update. How each study uses rilimogene glafolivec is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 9
- Docetaxel and PROSTVAC for Metastatic Castration-Sensitive Prostate CancerCompletedPhase 2National Cancer Institute (NCI)NCT02649855Written as PROSTVAC-FHow we know
- Prostvac in Patients With Biochemically Recurrent Prostate CancerCompletedPhase 2National Cancer Institute (NCI)NCT02649439Written as PROSTVAC-FHow we know
- Neoantigen DNA Vaccine in Combination With Nivolumab/Ipilimumab and PROSTVAC in Metastatic Hormone-Sensitive Prostate CancerCompletedPhase 1Washington University School of MedicineNCT03532217Written as PROSTVAC-FHow we know
- A Randomized, Double-blind, Phase 3 Efficacy Trial of PROSTVAC-V/F +/- GM-CSF in Men With Asymptomatic or Minimally Symptomatic Metastatic Castrate-Resistant Prostate CancerCompletedPhase 3Bavarian NordicNCT01322490Written as PROSTVAC-FHow we know
- Vaccine Therapy With PROSTVAC/TRICOM and Flutamide Versus Flutamide Alone to Treat Prostate CancerCompletedPhase 2National Cancer Institute (NCI)NCT00450463Written as PROSTVAC-F/ TRICOMHow we know
- Vaccine Plus Booster Shots in Men With Prostate Cancer Undergoing Treatment With Radical ProstatectomyCompletedPhase 2National Cancer Institute (NCI)NCT02153918Written as PROSTVAC-F/TRICOMHow we know
- Sequential Vaccinations in Prostate Cancer PatientsCompletedPhase 1/2National Cancer Institute (NCI)NCT00060528Written as Recombinant Fowlpox-PSA (L155)-TRICOM (PROSTVAC-F/TRICOM)How we know
- Docetaxel and Prednisone With or Without Vaccine Therapy in Treating Patients With Metastatic Hormone-Resistant Prostate CancerTerminatedPhase 2National Cancer Institute (NCI)NCT01145508Written as Recombinant Fowlpox-PSA(L155)/TRICOM VaccineHow we know
- A Phase II Study of PROSTVAC-V (Vaccinia)/TRICOM and PROSTVAC-F (Fowlpox)/TRICOM With GM-CSF in Patients With PSA Progression After Local Therapy for Prostate CancerCompletedPhase 2National Cancer Institute (NCI)NCT00108732Written as Recombinant Fowlpox-PSA(L155)/TRICOM VaccineHow we know
Given beside what is tested · 2 — rilimogene glafolivec is usual care or a partner of the new treatment
- Combination Immunotherapy in Biochemically Recurrent Prostate CancerCompletedPhase 2National Cancer Institute (NCI)NCT03315871Written as Antigen direct immunotherapy: PROSTVAC-FHow we know
- Enzalutamide in Combination With PSA-TRICOM in Patients With Non-Metastatic Castration Sensitive Prostate CancerCompletedPhase 2National Cancer Institute (NCI)NCT01875250Written as PROSTVAC-F (Fowlpox)/TRICOMHow we know
Codes
What other systems call rilimogene glafolivec · ClinicalTrials.gg INT015509
- UNII (FDA) 7PLH7RM47TRILIMOGENE GLAFOLIVECOne source FDA
- NCI Thesaurus C29560Rilimogene GlafolivecOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | 7PLH7RM47T | RILIMOGENE GLAFOLIVEC | One source FDA |
| NCI Thesaurus | C29560 | Rilimogene Glafolivec | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.